C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The options require continued employment through each vesting date and carry an exercise price equal to the grant-date closing price.

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) granted a new employee non-qualified stock options to purchase 85,480 common shares as an employment inducement. The grant was made on November 2, 2026, under Nasdaq Listing Rule 5635(c)(4), with an exercise price equal to the stock’s closing price that day.

The options vest over four years: 25% on the first anniversary of the employee’s start date and the remainder in thirty-six equal monthly installments thereafter. Each vesting date requires continued employment.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options to purchase 85,480 common shares granted to one new employee create potential dilution upon exercise.

Key Figures

Option shares: 85,480 shares Vesting period: Four years First vesting tranche: 25% +1 more

Option shares

85,480 shares

Granted to one new employee

Vesting period

Four years

Inducement Grant

First vesting tranche

25%

Vests on the first-year anniversary of the employee’s start date

Subsequent installments

36 equal monthly installments

Remaining shares vest after the first-year anniversary

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-qualified stock options financial

"non-qualified stock options to purchase 85,480 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on November 2, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com 

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did C4 Therapeutics grant to its new employee?

C4 Therapeutics granted non-qualified stock options to purchase 85,480 common shares to one new employee on November 2, 2026. The exercise price equals the stock’s closing price on the grant date.

What is the vesting schedule for C4 Therapeutics’ inducement grant?

The options vest over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder in thirty-six equal monthly installments thereafter. Vesting requires continued employment through each vesting date.